---
title: Micro Ribonucleic Acid (RNA) as Cholinergic Tone and Inflammatory Regulator in Inflammatory Bowel Disease
nct_id: NCT00734331
overall_status: COMPLETED
sponsor: Tel-Aviv Sourasky Medical Center
study_type: OBSERVATIONAL
primary_condition: Inflammatory Bowel Disease
countries: Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00734331.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00734331"
ct_last_update_post_date: 2020-06-16
last_seen_at: "2026-05-12T06:24:36.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Micro Ribonucleic Acid (RNA) as Cholinergic Tone and Inflammatory Regulator in Inflammatory Bowel Disease

**NCT ID:** [NCT00734331](https://clinicaltrials.gov/study/NCT00734331)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Tel-Aviv Sourasky Medical Center
- **Collaborators:** Hebrew University of Jerusalem
- **Conditions:** Inflammatory Bowel Disease
- **Start Date:** 2008-09
- **Completion Date:** 2009-09
- **CT.gov Last Update:** 2020-06-16

## Brief Summary

There is a reciprocal relationship between the central nervous system and the immune system. Stimulation of the vagus nerve results in secretion of acetylcholine (Ach) which decreases secretion of pro-inflammatory cytokines. Acetylcholine esterase is an enzyme that neutralizes Ach and thus, involves in regulation of Ach levels, and in the cholinergic tone and inflammatory state.

MicroRNAs (miRs) are evolutionarily conserved, RNAs that regulate gene expression. The investigators hypothesized that miRs controlling systemic communication processes function in one tissue in response to signals (i.e. neuronal, hormonal or others) from another.

Specifically, the investigators hypothesized that miRs control the inflammatory response in inflammatory bowel diseases through regulation of expression of messenger RNA of AchE.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Inflammatory bowel disease patients under going colonoscopy

Exclusion Criteria:

* Debilitated patients who need an apotropsy
* Age \< 18 or age \> 75
* Pregnant women
* Evidence of previous or current cancer
* Inflammatory disease other than IBD
```

## Arms

- **IBD** — Inflammatory bowel disease patients
- **Control** — Average risk patients undergoing screening colonoscopy

## Primary Outcomes

- **Elevated expression of specific micro RNAs that regulate the expression of the enzyme Acetylcholine esterase in inflammatory bowel disease patients compared to healthy controls.** _(time frame: one year)_

## Secondary Outcomes

- **A statistically significant relation between micro RNA expression and disease activity and inflammatory indices** _(time frame: one year)_

## Locations (1)

- Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.tel aviv sourasky medical center|tel aviv||israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00734331.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00734331*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*